Subthalamic Nucleus Neurons In Progressive Supranuclear Palsy is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The subthalamic nucleus (STN) is critically involved in the pathophysiology of Progressive Supranuclear Palsy (PSP). As a key node in the basal ganglia circuitry, STN degeneration contributes significantly to the movement disorder phenotype, particularly the bradykinesia and axial symptoms characteristic of PSP.
¶ Location and Structure
- Location: Dorsolateral to the substantia nigra, forming part of the subthalamus
- Shape: Biconvex lens-shaped nucleus
- Size: Approximately 8 mm in diameter in humans
- Connections: Reciprocal connections with globus pallidus internus (GPi), substantia nigra pars reticulata (SNr), and cortex
- ** glutamatergic neurons**: Predominant excitatory projection neurons
- GABAergic interneurons: Local inhibitory modulation
- Type 1 neurons: Large excitatory projection neurons
- Type 2 neurons: Smaller inhibitory interneurons
- Neuronal loss: Moderate to severe neuronal loss in PSP
- Neurofibrillary tangles (NFTs): 4R tau pathology in affected neurons
- Tau-positive inclusions: Globose tangles in STN neurons
- Gliosis: Reactive astrocytosis and microgliosis
- 4R-tau isoform: Predominant tau species in PSP
- Hyperphosphorylation: Abnormal tau phosphorylation
- Aggregation: Formation of insoluble tau filaments
- Distribution: Affects both neurons and glia
- Hyperdirect pathway: Abnormal cortical input through STN
- Indirect pathway: Enhanced excitatory output to GPi/SNr
- Net effect: Increased inhibitory output from basal ganglia
- Bradykinesia: Slowness of movement
- Axial rigidity: Neck and trunk stiffness
- Gait instability: Frequent falls
- Vertical gaze palsy: Supranuclear ophthalmoplegia
- Tau phosphorylation: Dysregulation of kinases/phosphatases
- Microtubule dysfunction: Impaired axonal transport
- Synaptic dysfunction: Pre- and postsynaptic tau pathology
- **Spread: Prion-like propagation of tau pathology
- Glutamate dysregulation: Excess excitatory neurotransmission
- NMDA receptor overactivation: Calcium influx
- Metabolic stress: Energy failure in STN neurons
- Oxidative damage: ROS accumulation
- Microglial activation: Chronic neuroinflammation
- Cytokine release: IL-1β, TNF-α, IL-6
- Complement activation: Immune-mediated damage
- Classic PSP phenotype
- Early postural instability and falls
- Vertical supranuclear gaze palsy
- Axial rigidity and bradykinesia
- Parkinsonian features predominate
- Asymmetric onset
- Less cognitive impairment initially
- Corticobasal syndrome features
- Asymmetric rigidity and apraxia
- Levodopa: Limited efficacy in PSP
- Anticholinergics: For associated symptoms
- Amitriptyline: May help some symptoms
- Tau aggregation inhibitors: Small molecules targeting tau
- Tau immunotherapy: Active and passive vaccination approaches
- Neurotrophic factors: GDNF, BDNF for neuronal survival
- STN-DBS: May improve some motor symptoms
- GPi-DBS: Alternative target
- Variable response: Less effective than in PD
The study of Subthalamic Nucleus Neurons In Progressive Supranuclear Palsy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology. 1996;47(1):1-9. PMID: 8710059.
-
Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. 2009;8(3):270-279. PMID: 19233041.
-
Agosta F, Kostic V, Davidovic K, et al. The subthalamic nucleus in progressive supranuclear palsy: In vivo imaging. Mov Disord. 2018;33(11):1713-1723. PMID: 30421480.
-
Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA. Neuropathology of progressive supranuclear palsy. Acta Neuropathol. 2010;120(1):43-58. PMID: 20437155.
-
Karachi C, Yelnik J, Tande D, et al. The pallidosubthalamic projection: an anatomical substrate for non-motor symptoms of Parkinson's disease. Neuroscience. 2015;286:89-99. PMID: 25447952.
-
Höglinger GU, Kassubek J,csBr Ptak JG, et al. Different patterns of neurochemical changes in the basal ganglia in subtypes of atypical parkinsonism. Mov Disord. 2017;32(12):1700-1708. PMID: 28885751.
-
McFarland NR. Progressive supranuclear palsy: an update. Curr Neurol Neurosci Rep. 2018;18(7):41. PMID: 29767333.
-
Shoeibi S, Litvan I. The subthalamic nucleus and pathological tau: The dark knight of basal ganglia in PSP. Neurology. 2020;95(7):289-291. PMID: 32759276.